Pharmacokinetics and biodisposition of poly(vinyl alcohol) in rats and mice.

Poly(vinyl alcohol) (PVA) of various molecular weight (MW=10,560-116,600) was successfully labeled with fluorescein isothiocyanate isomer I (FITC) according to the method of de Belder and Granath. A high-performance size-exclusion chromatographic procedure was developed for the quantitative analysis of FITC-labeled poly(vinyl alcohol) (F-PVA) in biological samples. F-PVA (80 K) disappeared slowly from the blood circulation according to the first-order kinetics (t1/2=7 h) after intravenous injection to rats. A dose-independent behavior of F-PVA (80 K) was observed in the blood circulation, in the tissue distribution and in the urinary and fecal excretions. This suggested that PVAs are eliminated exclusively by the mechanisms that do not involve saturable transport processes. Furthermore, it was found that PVAs are very stable in the body because no degradation product was detected in the urine and feces. 125I-labeled poly(vinyl alcohol) (125I-PVA) was prepared by introducing tyramine residues to the hydroxyl groups of PVA molecules by the 1,1'-cabonyldiimidazole (CDI) activation method. 125I-PVA (80 K) was retained in the blood circulation for several days after intravenous injection to mice. Although the tissue distribution of PVAs was small, a significant accumulation into the liver and the spleen was observed. Fluorescence microscopic examination of paraffin section of the liver revealed that F-PVA (80 K) was endocytosed by the liver parenchymal cells. 125I-PVA (80 K) captured by liver was slowly transported via the bile canaliculi and gall bladder to the intestine and excreted in the feces. It was suggested, therefore, a long time is necessary for 125I-PVA (80 K) to be excreted perfectly from the body.

[1]  N. L. Krinick,et al.  Soluble Polymers as Targetable Drug Carriers , 1991 .

[2]  R. Langer,et al.  Drug delivery and targeting. , 1998, Nature.

[3]  A. Richter,et al.  MODIFIED POLYVINYL ALCOHOL‐BENZOPORPHYRIN DERIVATIVE CONJUGATES AS PHOTOTOXIC AGENTS , 1993, Photochemistry and photobiology.

[4]  A. Seligman,et al.  Polyvinyl pyrrolidone as a plasma expander; studies on its excretion, distribution and metabolism. , 1952, The New England journal of medicine.

[5]  J. Kopeček,et al.  Effect of molecular weight (Mw) of N-(2-hydroxypropyl)methacrylamide copolymers on body distribution and rate of excretion after subcutaneous, intraperitoneal, and intravenous administration to rats. , 1987, Journal of biomedical materials research.

[6]  Teruo Okano,et al.  Challenges in polymer therapeutics: state of the art and prospects of polymer drugs. , 2003, Advances in experimental medicine and biology.

[7]  Tetsuro Tanaka,et al.  Evidence for receptor-mediated hepatic uptake of pullulan in rats. , 2001, Journal of controlled release : official journal of the Controlled Release Society.

[8]  H. Maeda,et al.  Evaluation of Poly(vinyl alcohol) for Protein Tailoring: Improvements in Pharmacokinetic Properties of Superoxide Dismutase , 1993 .

[9]  J. Kopeček,et al.  Soluble synthetic polymers as potential drug carriers , 1984 .

[10]  K. Arfors,et al.  Stability of fluorescein labeled dextrans in vivo and in vitro. , 1976, Microvascular research.

[11]  D. Knook,et al.  Fluid endocytosis by rat liver and spleen. Experiments with 125I-labelled poly(vinylpyrrolidone) in vivo. , 1980, The Biochemical journal.

[12]  D. Knook,et al.  Clearance capacity of rat liver Kupffer, Endothelial, and parenchymal cells. , 1981, Gastroenterology.

[13]  S. Kanoh,et al.  Polysaccharides as drug carriers: biodisposition of fluorescein-labeled dextrans in mice. , 1997, Biological & pharmaceutical bulletin.

[14]  K. Granath,et al.  Preparation and properties of fluorescein-labelled dextrans , 1973 .

[15]  T. Tanaka,et al.  Pharmacokinetics and biodisposition of fluorescein-labeled arabinogalactan in rats. , 2000, International journal of pharmaceutics.

[16]  S. Pizzo,et al.  A new procedure for the synthesis of polyethylene glycol-protein adducts; effects on function, receptor recognition, and clearance of superoxide dismutase, lactoferrin, and alpha 2-macroglobulin. , 1983, Analytical biochemistry.

[17]  F. Greenwood,et al.  THE PREPARATION OF I-131-LABELLED HUMAN GROWTH HORMONE OF HIGH SPECIFIC RADIOACTIVITY. , 1963, The Biochemical journal.

[18]  M T Hearn,et al.  1,1'-Carbonyldiimidazole-mediated immobilization of enzymes and affinity ligands. , 1987, Methods in enzymology.

[19]  R. Mehvar,et al.  Molecular-weight-dependent pharmacokinetics of fluorescein-labeled dextrans in rats. , 1992, Journal of pharmaceutical sciences.

[20]  Y. Ikada,et al.  Comparison of Body Distribution of Poly(vinyl alcohol) with Other Water‐soluble Polymers after Intravenous Administration , 1995, The Journal of pharmacy and pharmacology.

[21]  Y. Ikada,et al.  Tumor accumulation of poly(vinyl alcohol) of different sizes after intravenous injection. , 1998, Journal of controlled release : official journal of the Controlled Release Society.

[22]  R. Duncan The dawning era of polymer therapeutics , 2003, Nature Reviews Drug Discovery.

[23]  C. Larsen,et al.  High-performance size-exclusion chromatographic procedure for the determination of fluoresceinyl isothiocyanate dextrans of various molecular masses in biological media. , 1989, Journal of Chromatography A.

[24]  Hiroshi Maeda,et al.  Early Phase Tumor Accumulation of Macromolecules: A Great Difference in Clearance Rate between Tumor and Normal Tissues , 1998, Japanese journal of cancer research : Gann.